Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Armata PharmaceuticalsARMP +19.95%27 3-1 Month Momentum % is -38.61% as of Jul. 19, 2026. GuruFocus rates ARMP with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,387 Biotechnology companies, Armata Pharmaceuticals ranks worse than 88.1% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-19), Armata Pharmaceuticals's 3-1 Month Momentum % is -38.61%.
The industry rank for Armata Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
ARMP's 3-1 Month Momentum % is ranked worse than 88.1% of 1387
companies
in the Biotechnology industry
Industry Median: -13.58
vs ARMP: -38.61
Armata Pharmaceuticals (AMEX:ARMP) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Armata Pharmaceuticals 3-1 Month Momentum % Related Terms
ARMP vs NAGE, ALXO, LYEL: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Armata Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Armata Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's 3-1 Month Momentum % falls into.
Armata Pharmaceuticals (AMEX:ARMP) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals (ARMP) has a 3-1 Month Momentum % of -38.61% as of Jul. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Armata Pharmaceuticals and its competitors. According to the industry distribution chart, Armata Pharmaceuticals ranks #1222 out of 1387 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Armata Pharmaceuticals' 3-1 Month Momentum % too high?
Armata Pharmaceuticals' current 3-1 Month Momentum % is -38.61%. Based on the distribution chart, Armata Pharmaceuticals ranks #1222 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Armata Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' 3-1 Month Momentum % compare to NAGE and ALXO?
According to the Biotechnology industry distribution chart, Armata Pharmaceuticals ranks #1222 out of 1387 companies for 3-1 Month Momentum %. This places Armata Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Armata Pharmaceuticals and its competitors. Armata Pharmaceuticals's current 3-1 Month Momentum % is -38.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (ARMP) has a current 3-1 Month Momentum % of -38.61%. The current 3-1 Month Momentum % is -38.61%. Armata Pharmaceuticals' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Armata Pharmaceuticals (ARMP), the current 3-1 Month Momentum % is -38.61% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
27GF Score
Get the complete analysis for ARMP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARMP has been successfully added to your 
